[SCHEDULE 13G/A] Stoke Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

TE Connectivity plc (TEL) – Form 4 insider transaction

EVP & General Counsel John S. Jenkins exercised 45,850 stock options at an exercise price of $105.86 on 28 Jul 2025, immediately selling the identical number of common shares in two open-market trades:

• 7,918 shares sold at a weighted-average $209.94
• 37,932 shares sold at a weighted-average $209.21

Estimated gross proceeds total ≈ $9.6 million. Following the transactions, Jenkins’ direct beneficial ownership fell from 70,475 to 24,625 shares (-65%), signalling a substantial reduction in personal exposure to TEL equity. No derivative securities remain outstanding under the exercised grant (expiring 9 Nov 2030). No other insider trades or company financial metrics were disclosed in this filing.

Positive

• None.

Negative

• Executive sells 100% of shares acquired via option exercise, cutting personal stake by ~65%, which can be interpreted as reduced long-term confidence.
• Gross proceeds of ≈ $9.6 m realised; scale of sale may pressure short-term sentiment toward TEL.

Insights

Securities Analyst

TL;DR: Large option exercise coupled with full share sale; insider ownership drops materially, typically a bearish signal.

The EVP & General Counsel monetised an entire 45,850-share option block, netting roughly $9.6 m at a 97% spread to strike. Because every exercised share was sold the same day, the transaction resembles a cashless exercise rather than a vote of confidence. Post-sale holdings decline ~65% to 24.6k shares, reducing alignment with outside shareholders. While single-insider sales don’t always foreshadow performance, the size and leadership level make this moderately negative for sentiment. There is no indication of a pre-arranged Rule 10b5-1 plan, increasing perceived discretion. Overall impact: limited to sentiment—not fundamentals—but worth monitoring for additional insider activity.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Stoke Therapeutics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

86150R107

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 86150R107

1

Names of Reporting Persons

Cowen Financial Products LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,173,258.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,173,258.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,173,258.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Stoke Therapeutics Inc
(b)	Address of issuer's principal executive offices: 3 Preston Ct, Bedford, MASSACHUSETTS 01730
Item 2.
(a)	Name of person filing: Cowen Financial Products LLC
(b)	Address or principal business office or, if none, residence: One Vanderbilt Avenue New York, NY 10017
(c)	Citizenship: Cowen Financial Products LLC - DELAWARE
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 86150R107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,173,258
(b)	Percent of class: 5.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Cowen Financial Products LLC - 3,173,258
	(ii) Shared power to vote or to direct the vote: Cowen Financial Products LLC - 0
	(iii) Sole power to dispose or to direct the disposition of: Cowen Financial Products LLC - 3,173,258
	(iv) Shared power to dispose or to direct the disposition of: Cowen Financial Products LLC - 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Cowen Financial Products LLC

Signature:	John Holmes
Name/Title:	John Holmes / Chief Operating Officer
Date:	07/29/2025

FAQ

How many TE Connectivity (TEL) shares did EVP John S. Jenkins sell?

He sold 45,850 common shares on 28 Jul 2025.

What was the average sale price for the TEL shares?

Weighted-average prices were $209.94 for 7,918 shares and $209.21 for 37,932 shares.

How many TEL shares does Jenkins now own?

His direct beneficial ownership stands at 24,625 shares after the transactions.

What was the option exercise price?

The stock options were exercised at $105.86 per share.

Were any derivative securities left outstanding?

No. The 45,850-share option grant was fully exercised; zero options remain from this grant.